Meformin and LY294002 treatment regulate angiogenesis process through PI3K-MAPK/AKT/mTOR signaling pathways in mammary tumors.

dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-11-26T15:46:02Z
dc.date.available2018-11-26T15:46:02Z
dc.date.created2018-11-26T15:46:02Z
dc.date.issued2018-01-01
dc.identifierClinical Cancer Research. Philadelphia: Amer Assoc Cancer Research, v. 24, n. 1, p. 77-78, 2018.
dc.identifier1078-0432
dc.identifierhttp://hdl.handle.net/11449/159994
dc.identifierWOS:000419180000127
dc.languageeng
dc.publisherAmer Assoc Cancer Research
dc.relationClinical Cancer Research
dc.relation4,929
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.titleMeformin and LY294002 treatment regulate angiogenesis process through PI3K-MAPK/AKT/mTOR signaling pathways in mammary tumors.
dc.typeOtros


Este ítem pertenece a la siguiente institución